Key result
The ABCB1 C3435T polymorphism (TT homozygotes) was associated with a significantly increased risk of early major adverse cardiovascular events (OR 1.77) compared to CC homozygotes in CAD patients treated with clopidogrel.
Why the study?
Does the ABCB1 C3435T polymorphism increase the risk of MACE or affect platelet activity in CAD patients treated with clopidogrel?
Population
Coronary artery disease patients treated with clopidogrel
Comparison
ABCB1 C3435T polymorphism vs ABCB1 C3435T wild-type (C allele or CC genotype)
Design
Meta-analysis
Follow-up
up to 1.7 years
Authors
Loading...
May warrant caution with clopidogrel in ABCB1 TT carriers; extends observational pharmacogenomics but leaves practice change open.
Meta-Analysis
Does the ABCB1 C3435T polymorphism increase the risk of MACE or affect platelet activity in CAD patients treated with clopidogrel?
Odds Ratio: 1.77 (95% CI 1.19–2.63)
p-value: p=0.005
The ABCB1 C3435T polymorphism is associated with an increased risk of MACE in CAD patients receiving a 300 mg clopidogrel loading dose, but a decreased risk of bleeding for TT homozygotes.
Su et al. (2012) conducted a meta-analysis in Coronary Artery Disease (CAD). ABCB1 C3435T polymorphism (TT genotype) vs. CC genotype was evaluated on Early major adverse cardiovascular events (MACE) (OR 1.77, 95% CI 1.19 to 2.63, p=0.005). The ABCB1 C3435T polymorphism (TT homozygotes) was associated with a significantly increased risk of early major adverse cardiovascular events (OR 1.77) compared to CC homozygotes in CAD patients treated with clopidogrel.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: